Neximmune Inc
NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a vivo directly injectable modality platform. The company's product candidates incl… Read more
Neximmune Inc (NEXI) - Total Assets
Latest total assets as of June 2024: $5.86 Million USD
Based on the latest financial reports, Neximmune Inc (NEXI) holds total assets worth $5.86 Million USD as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Neximmune Inc - Total Assets Trend (2018–2023)
This chart illustrates how Neximmune Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Neximmune Inc - Asset Composition Analysis
Current Asset Composition (December 2023)
Neximmune Inc's total assets of $5.86 Million consist of 62.9% current assets and 37.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.3% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2023)
This chart illustrates how Neximmune Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neximmune Inc's current assets represent 62.9% of total assets in 2023, a decrease from 87.2% in 2018.
- Cash Position: Cash and equivalents constituted 37.3% of total assets in 2023, up from 3.0% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Neximmune Inc Competitors by Total Assets
Key competitors of Neximmune Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Neximmune Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Neximmune Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Neximmune Inc is currently not profitable relative to its asset base.
Neximmune Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.66 | 2.95 | 3.65 |
| Quick Ratio | 0.66 | 2.66 | 3.65 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-1.61 Million | $ 12.23 Million | $ 8.01 Million |
Neximmune Inc - Advanced Valuation Insights
This section examines the relationship between Neximmune Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -80.0% |
| Total Assets | $8.59 Million |
| Market Capitalization | $117.84 USD |
Valuation Analysis
Below Book Valuation: The market values Neximmune Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Neximmune Inc's assets decreased by 80.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Neximmune Inc (2018–2023)
The table below shows the annual total assets of Neximmune Inc from 2018 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $8.59 Million | -80.04% |
| 2022-12-31 | $43.06 Million | -52.70% |
| 2021-12-31 | $91.03 Million | +705.52% |
| 2020-12-31 | $11.30 Million | -17.62% |
| 2019-12-31 | $13.72 Million | -3.00% |
| 2018-12-31 | $14.14 Million | -- |